Essays about: "combination therapy"
Showing result 21 - 25 of 76 essays containing the words combination therapy.
-
21. Role of CDK4/CDK6 inhibitors: Ribociclib, Palbocilcib and Abemacilcib in treatment of metastatic breast cancer
University essay from Linnéuniversitetet/Institutionen för kemi och biomedicin (KOB)Abstract : Breast cancer is the most common cancer among women in Sweden and globally. Socio-demographic, genetic and productive factors together with some endogenous and exogenous hormones and lifestyle are some of the risk factors that can cause this type of cancer. READ MORE
-
22. Treating latent tuberculosis : Efficacy of rifapentine plus isoniazid combination therapy vs. isoniazid monotherapy
University essay from Linnéuniversitetet/Institutionen för kemi och biomedicin (KOB)Abstract : Latent tuberculosis infection (LTBI) is a global health issue that affects approximately one quarter of the world’s population. It refers to a state of persistent immune response to Mycobacterium tuberculosis without clinical evidence of active tuberculosis (TB). READ MORE
-
23. Investigation of endogenous p21 expression and its correlation to therapy resistance in high-risk neuroblastoma
University essay from KTH/ProteinvetenskapAbstract : Neuroblastoma (NB) is a childhood cancer with a highly complex nature. High-risk NB patients undergo intensive treatment regimens that are often followed by long-term side effects. This, in addition to the emergence of resistant cancer cells, highlights a need for novel therapeutic targets and treatment strategies to improve outcome in NB. READ MORE
-
24. Antibiotic combination therapies against carbapenamse producing Klebsiella pneumoniae
University essay from Uppsala universitet/Institutionen för biologisk grundutbildningAbstract : The treatment options for multidrug resistant bacteria are dwindling and it is an important issue of research in medicine to solve. One of the more problematic bacterial species is Klebsiella pneumoniae, it can cause infections with high morbidity that are difficult to treat. READ MORE
-
25. Risk of neutropenia and healthcare resource utilization in patients with metastatic breast cancer treated with CDK4/6 inhibitors in real-world setting
University essay from Örebro universitet/Institutionen för medicinska vetenskaperAbstract : Introduction: In patients with metastatic estrogen-receptor (ER) positive breast cancer, the current standard of care as first or second line treatment is a combination of endocrine therapy with a CDK 4/6-inhibitor. Neutropenia is a dose-limiting toxicity of CDK 4/6 inhibitors leading to dose adjustment and treatment discontinuation in a considerable number of patients. READ MORE